Coherus Nears FDA Filing Date For Humira Biosimilar
R&D Spend Ramps Up Ahead Of Planned 2023 Launch
Coherus BioSciences has committed to oncology biosimilars over inflammation projects but is continuing to work towards a filing for biosimilar Humira (adalimumab) by 31 December. Armed with more than $200m of fresh capital, management discussed future business development plans.
